Olink Bioscience Appoints Patrik Dahlén as Chairman of the Board

Olink Bioscience, a rapidly growing provider of innovative tools for proteomics and genomics, has today announced the appointment of Dr. Patrik Dahlén as Chairman of the Board. As the former CEO of global cancer diagnostics company Dako and with experience from several smaller fast developing biotech companies, Dr. Dahlén will bring invaluable industry insight and a fresh perspective to Olink Bioscience continued expansion. Professor Ulf Landegren, co-founder and the company´s former Chairman of the Board will continue to serve on the BoD and he will continue to bring the company valuable contacts with the scientific community in Uppsala and internationally

Dr. Dahlén has occupied high level positions within the diagnostics and life sciences sector for over 15 years. Prior to his four year tenure at Dako from 2005 to January 2009 Dr. Dahlen was CEO of the Danish biotech company Biolmage and previous to that president of lifesciences and senior vice president at PerkinElmer. Dr. Dahlen currently holds other board positions which include Proxeon, DxS Diagnostics, and has been a board member for DakoCytomation and Cantion.

Commenting on his appointment, Dr. Dahlen said: "I am delighted to be joining Olink Bioscience as the Chairman. Olink Bioscience has a tremendous growth potential in protein detection and characterization in research applications today based on the Duolink(R) product. In addition, the company has the potential to broaden these applications to include breakthrough nucleic acid detection systems. In the near future, all these applications will have a great diagnostic potential and I look forward to working with Olink Bioscience to help maximize the value of the company from its potential. "

"We are excited to have Patrik on board as our Chairman of the Board at this point in time as we are preparing for rapid expansion of our Duolink in situ protein detection platform in the R&D market as well as making plans for entering the IVD arena. Patriks experience from cancer diagnostics and great knowledge of the biotech and IVD industry will be extremely valuable in growing our company"" says Björn Ekström; President and CEO of Olink Bioscience.

About Olink Bioscience

Olink Bioscience is a privately held biotech supply company based in Uppsala, Sweden founded in 2004. The company controls significant IP covering technologies related to detection and analysis of proteins and nucleic acids. These technologies are commercialized as proprietary Olink Bioscience products, in spin-out companies and in collaboration with external organization. In 2007 Olink Bioscience introduced the Duolink product line for in situ detection of proteins, protein interactions and protein modifications. These products are based on PLA(TM), a proximity ligation assay technology which use dual recognition of the analyte in combination with a DNA amplification based reporter system, resulting in unparalleled sensitivity and specificity. The technology is available as reagent kits and contract research projects through Olink Bioscience.

For information please contact:

Björn Ekström, President and CEO Olink AB

Phone: +46 18444 3971

bjorn.ekstrom@olink.com